Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus

NCT01293669 is registered in ClinicalTrials.gov with Targacept Inc. as lead sponsor.

NCT NCT01293669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01293669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Lead sponsor
Targacept Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2011
Completion date
January 31, 2012
Enrollment
440 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus